Table 3

Long-term all-cause mortality and risk of major adverse cardiovascular events in patients with low hs-cTnT concentrations

Peak Hs-cTnT concentrations (ng/l)
<5 ng/L5–14 ng/L
Number of patients, n (%)69 090 (62)42 826 (38)
All-cause mortality
 Number of deaths, n (%)1769 (2.6)5534 (13)
 Deaths per 10 000 person-years, (95% CI)38.9 (38.8–39.1)212 (211–213)
 1-year crude cumulative mortality, (95% CI)0.33% (0.29–0.37)1.99% (1.86–2.12)
 5-year crude cumulative mortality, (95% CI)1.55% (1.46–1.65)9.07% (8.81–9.35)
 Unadjusted HR, (95% CI)Ref. (1.0)5.72 (5.42–6.04)
 Age-adjusted and sex-adjusted HR, (95% CI)Ref. (1.0)1.83 (1.73–1.95)
Multivariable adjusted HR*, (95% CI)Ref. (1.0)1.70 (1.60–1.80)
MACE†
 Number of patients who survived the index visit69 08642 791
 Number of events, n (%)2326 (3.3)6276 (15)
 Events per 10 000 person-years, (95% CI)52.1 (50.0–54.3)258 (252–265)
 1-year crude cumulative event risk, (95% CI)0.61% (0.56–0.0.67)3.74% (3.57–3.92)
 5-year crude cumulative event risk, (95% CI)2.44% (2.32–2.57)12.2% (11.9–12.6)
 Unadjusted HR, (95% CI)Ref. (1.0)4.98 (4.75–5.23)
 Age-adjusted and sex-adjusted HR, (95% CI)Ref. (1.0)1.81 (1.72–1.91)
Multivariable adjusted HR*, (95% CI)Ref. (1.0)1.61 (1.53–1.70)
  • *Multivariable adjustment was made for the following time-dependent variables: age, sex, eGFR, prior myocardial infarction, heart failure, prior stroke, prior chronic obstructive pulmonary disease, atrial fibrillation, diabetes and treatment with aspirin, P2Y12-inhibitors (clopidogrel, prasugrel, dipyramidol, and ticagrelor), oral anticoagulants (Warfarin and direct oral anticoagulants (DOAC)), beta-blockers, angiotensin-converting enzyme inhibitor/angiotensin receptor blockers and statins.

  • †Includes myocardial infarction, heart failure hospitalisation, stroke or cardiovascular death.

  • eGFR, estimated glomerular filtration rate; MACE, major adverse cardiovascular event.